Pretenders and Contenders: Inflammation, C-Reactive Protein, and Interleukin-6.
作者信息
Daniels Lori B
机构信息
University of California San Diego Health, La Jolla, CA
出版信息
J Am Heart Assoc. 2017 Oct 24;6(10):e007490. doi: 10.1161/JAHA.117.007490.
Abstract
摘要
相似文献
1
Pretenders and Contenders: Inflammation, C-Reactive Protein, and Interleukin-6.伪装者与竞争者：炎症、C反应蛋白和白细胞介素-6
J Am Heart Assoc. 2017 Oct 24;6(10):e007490. doi: 10.1161/JAHA.117.007490.
2
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.在稳定性冠心病中炎症生物标志物白细胞介素-6 和 C 反应蛋白与结局：来自 STABILITY（通过起始达泊利德治疗稳定动脉粥样硬化斑块）试验的经验。
J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.
3
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.白细胞介素-6 与急性冠状动脉综合征患者不良结局风险：来自 SOLID-TIMI 52（达肝素治疗急性心肌梗死 52 试验中斑块稳定）试验的观察结果。
J Am Heart Assoc. 2017 Oct 24;6(10):e005637. doi: 10.1161/JAHA.117.005637.
4
Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice.载脂蛋白 E 缺陷型小鼠中脂蛋白相关磷脂酶 A2 的抑制作用可改善炎症反应并减少动脉粥样硬化斑块形成。
PLoS One. 2011;6(8):e23425. doi: 10.1371/journal.pone.0023425. Epub 2011 Aug 31.
5
Biomarkers associated with coronary high-risk plaques.与冠状动脉高危斑块相关的生物标志物。
J Thromb Thrombolysis. 2022 Nov;54(4):647-659. doi: 10.1007/s11239-022-02709-2. Epub 2022 Oct 7.
6
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study.C反应蛋白、白细胞介素-6和纤维蛋白原作为冠心病的预测指标：PRIME研究
Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1255-61. doi: 10.1161/01.ATV.0000079512.66448.1D. Epub 2003 May 29.
7
The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice.脂蛋白相关磷脂酶 A2 的抑制作用对 LDLR 缺陷型小鼠的动脉粥样硬化具有有益影响。
Acta Pharmacol Sin. 2011 Oct;32(10):1253-8. doi: 10.1038/aps.2011.127. Epub 2011 Aug 15.
8
Darapladib for the treatment of cardiovascular disease.用于治疗心血管疾病的达拉匹林。
Expert Rev Cardiovasc Ther. 2015 Jan;13(1):33-48. doi: 10.1586/14779072.2015.986466.
9
Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.血清炎症生物标志物与 FDG PET/CT 评估的斑块炎症的关系：dal-PLAQUE 研究。
JACC Cardiovasc Imaging. 2013 Oct;6(10):1087-1094. doi: 10.1016/j.jcmg.2013.03.009.
10
Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis.心血管危险因素与坏死核心和粥样斑块大小的关系：一项连续血管内超声射频数据分析。
Int J Cardiovasc Imaging. 2012 Apr;28(4):695-703. doi: 10.1007/s10554-011-9882-6. Epub 2011 May 19.
引用本文的文献
1
The higher serum uric acid to high-density lipoprotein cholesterol ratio is associated with increased risk of chronic obstructive pulmonary disease: result from NHANES 2011-2018.血清尿酸与高密度脂蛋白胆固醇比值升高与慢性阻塞性肺疾病风险增加相关：来自2011 - 2018年美国国家健康与营养检查调查的结果
BMC Pulm Med. 2025 Jul 4;25(1):322. doi: 10.1186/s12890-025-03743-5.
2
Impaired Peripheral Microvascular Function and Risk of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease.冠状动脉疾病患者外周微血管功能受损与主要不良心血管事件风险
Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1801-1809. doi: 10.1161/ATVBAHA.121.316083. Epub 2021 Mar 18.
3
Sex differences in the inflammatory response to stress and risk of adverse cardiovascular outcomes among patients with coronary heart disease.压力引起的炎症反应在性别间的差异，以及其对冠心病患者不良心血管结局风险的影响。
Brain Behav Immun. 2020 Nov;90:294-302. doi: 10.1016/j.bbi.2020.09.001. Epub 2020 Sep 8.
4
The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.托珠单抗联合血液吸附治疗 SARS-CoV-2 相关肺炎患者：1 例报告
Nephron. 2020;144(9):459-462. doi: 10.1159/000509738. Epub 2020 Jul 21.
5
Young Women With Coronary Artery Disease Exhibit Higher Concentrations of Interleukin-6 at Baseline and in Response to Mental Stress.年轻女性冠心病患者在基线和精神应激时白细胞介素-6 浓度更高。
J Am Heart Assoc. 2018 Dec 4;7(23):e010329. doi: 10.1161/JAHA.118.010329.
6
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.炎老化：与衰老、心血管疾病和虚弱有关的慢性炎症。
Nat Rev Cardiol. 2018 Sep;15(9):505-522. doi: 10.1038/s41569-018-0064-2.
本文引用的文献
1
Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.在稳定性冠心病中炎症生物标志物白细胞介素-6 和 C 反应蛋白与结局：来自 STABILITY（通过起始达泊利德治疗稳定动脉粥样硬化斑块）试验的经验。
J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077.
2
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.白细胞介素-6 与急性冠状动脉综合征患者不良结局风险：来自 SOLID-TIMI 52（达肝素治疗急性心肌梗死 52 试验中斑块稳定）试验的观察结果。
J Am Heart Assoc. 2017 Oct 24;6(10):e005637. doi: 10.1161/JAHA.117.005637.
3
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
4
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.白细胞介素-6 受体拮抗剂托珠单抗单次给药对非 ST 段抬高型心肌梗死患者炎症和肌钙蛋白 T 释放的影响：一项双盲、随机、安慰剂对照的 2 期临床试验。
Eur Heart J. 2016 Aug 7;37(30):2406-13. doi: 10.1093/eurheartj/ehw171. Epub 2016 May 8.
5
Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis.炎症细胞因子与冠心病风险：一项新的前瞻性研究和更新的荟萃分析。
Eur Heart J. 2014 Mar;35(9):578-89. doi: 10.1093/eurheartj/eht367. Epub 2013 Sep 10.
6
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.心血管炎症减少试验的原理和设计：对动脉粥样硬化血栓形成炎症假说的检验。
Am Heart J. 2013 Aug;166(2):199-207.e15. doi: 10.1016/j.ahj.2013.03.018. Epub 2013 May 3.
7
C-reactive protein, fibrinogen, and cardiovascular disease prediction.C 反应蛋白、纤维蛋白原与心血管疾病预测。
N Engl J Med. 2012 Oct 4;367(14):1310-20. doi: 10.1056/NEJMoa1107477.
8
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.白细胞介素-6 受体作为预防冠心病的靶点：一项孟德尔随机分析。
Lancet. 2012 Mar 31;379(9822):1214-24. doi: 10.1016/S0140-6736(12)60110-X. Epub 2012 Mar 14.
9
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.白细胞介素-6 受体通路与冠心病：82 项研究的荟萃分析协作组
Lancet. 2012 Mar 31;379(9822):1205-13. doi: 10.1016/S0140-6736(11)61931-4. Epub 2012 Mar 14.
10
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.与C反应蛋白水平及冠心病风险相关的基因位点
JAMA. 2009 Jul 1;302(1):37-48. doi: 10.1001/jama.2009.954.
Zotero 插件